跳至主要内容
临床试验/NCT02838199
NCT02838199撤回4 期

Prospective, Open Label, Multicenter, Dual Arm, Randomized Trial of TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis

Seung-Jung Park2 个研究点 分布在 1 个国家开始时间: 2016年12月最近更新:
适应症

试验速览

阶段
4 期
状态
撤回
发起方
试验地点
2
主要终点
event rate of all-cause mortality

研究概览

简要总结

The purpose of this study is to determine that Transcatheter aortic valve replacement (TAVR) with SAPIEN 3 is superior to traditional surgical aortic valve replacement(SAVR) with bio-prosthesis regarding the rate of all-cause mortality at 1 year in patients with symptomatic severe aortic valve stenosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age must be at least 19 and less than 75 years old
  • Severe aortic valve stenosis with echocardiographically derived criteria: mean gradient > 40mmHg or jet velocity greater than 4.0 m/s AND an initial aortic valve area (AVA) of ≤ 0.8 cm
  • Echocardiogram must be within 3 months of the date of the procedure
  • Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA class II or greater.
  • The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

排除标准

  • Life expectancy <1 year due to medical illness
  • Suspected Malignancy
  • Inoperability evaluated by surgeon
  • Concomitant severe coronary artery disease not amenable for percutaneous coronary intervention
  • Concomitant severe mitral valve or significant aorta disease requiring surgery
  • Active bacterial endocarditis within 6 months of procedure
  • Leukopenia (WBC<3000 cell/mL), acute anemia (Hgb<8g/dL), thrombocytopenia (platelet < 50000 cell/mL)
  • Intracardiac thrombus
  • A known contraindication or hypersensitivity to all anticoagulation regimens, or inability to be anticoagulated for the study procedure.
  • Native aortic annulus size < 18 mm or > 25 mm as measured by echocardiogram.
  • Expectation that patient will not improve despite treatment of aortic stenosis
  • Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.

结局指标

主要结局

event rate of all-cause mortality

时间窗: 1 year

次要结局

  • event rate of myocardial Infarction(31 days to the 1 year)
  • event rate of acute kidney injury(31 days to the 1 year)
  • event rate of other TAVR-related complication(31 days to the 1 year)
  • event rate of free from atrial fibrillation(30days and 1 year)
  • event rate of bleeding(31 days to the 1 year)
  • event rate of vascular access site and access-related complication(31 days to the 1 year)
  • event rate of prosthetic valve dysfunction(31 days to the 1 year)
  • event rate of composite event for device success, early safety, clinical efficacy(31 days to the 1 year)
  • event rate of cardiovascular mortality(31 days to the 1 year)
  • event rate of all Stroke and transient ischemic attack(31 days to the 1 year)
  • event rate of structural valve deterioration(31 days to the 1 year)
  • NYHA (New York Heart Association Functional Classification)(30days and 1 year)
  • event rate of permanent pacemaker insertion(31 days to the 1 year)
  • Valve area(30days and 1 year)

研究者

发起方
Seung-Jung Park
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Seung-Jung Park

professor of medicine

Asan Medical Center

研究点 (2)

Loading locations...

相似试验